GH1 and acute lymphoblastic leukemia: [29–32] Also, it is suggested that radiotherapy to the head can result in a low growth hormone level [33], which is likely to contribute to the development of metabolic syndrome [34] and, by being a modulator of myocardial structure and function [35], is associated with a higher cardiovascular risk for subgroups of CCS, for example ALL survivors treated with cranial radiotherapy [36] Moreover, we found that radiotherapy to the lower extremities also was associated with a higher risk of hospitalizations for cardiovascular conditions, which was not shown before in literature.